Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced dosing of the first two participants in a Phase 2 clinical study of ABI-6250, the company’s investigational oral small-molecule entry inhibitor candidate, in participants with chronic hepatitis delta virus (HDV) infection.

The Phase 2 study is expected to enroll approximately 80 participants with chronic HDV infection and will evaluate two once-daily oral dose levels of ABI-6250. The study will evaluate safety, pharmacokinetics, pharmacodynamics and efficacy, including changes from baseline in HDV RNA and alanine aminotransferase levels. Initial data from the study is expected in the fourth quarter of 2027.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.